By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.

Specifically, the deal is for the evaluation of the technology for matching the most appropriate targeted therapies with lung cancer patients.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.